[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 77, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.79, "open": 8.74, "dayLow": 8.051, "dayHigh": 8.051, "regularMarketPreviousClose": 8.79, "regularMarketOpen": 8.74, "regularMarketDayLow": 8.051, "regularMarketDayHigh": 8.051, "beta": 0.011, "volume": 24, "regularMarketVolume": 24, "averageVolume": 2916, "averageVolume10days": 1290, "averageDailyVolume10Day": 1290, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 5.45, "fiftyTwoWeekHigh": 16.75, "fiftyDayAverage": 9.43322, "twoHundredDayAverage": 9.583325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 56344162, "bookValue": 6.93, "priceToBook": 1.1617604, "netIncomeToCommon": -187358000, "52WeekChange": -0.060215056, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 8.051, "recommendationKey": "none", "totalCash": 808476992, "totalCashPerShare": 7.201, "ebitda": -189582000, "totalDebt": 389000, "quickRatio": 19.8, "currentRatio": 19.977, "totalRevenue": 47140000, "debtToEquity": 0.05, "revenuePerShare": 0.465, "returnOnAssets": -0.18146999, "returnOnEquity": -0.31511, "grossProfits": 47140000, "freeCashflow": -98995504, "operatingCashflow": -140430000, "revenueGrowth": 1.126, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -23.14473, "financialCurrency": "USD", "symbol": "NAMSW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -8.407285, "regularMarketPrice": 8.051, "corporateActions": [], "regularMarketTime": 1747252800, "longName": "NewAmsterdam Pharma Company N.V.", "shortName": "NewAmsterdam Pharma Company N.V", "regularMarketChange": -0.7390003, "regularMarketDayRange": "8.051 - 8.051", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2916, "fiftyTwoWeekLowChange": 2.6009998, "fiftyTwoWeekLowChangePercent": 0.4772477, "fiftyTwoWeekRange": "5.45 - 16.75", "fiftyTwoWeekHighChange": -8.699, "fiftyTwoWeekHighChangePercent": -0.5193433, "fiftyTwoWeekChangePercent": -6.0215054, "fiftyDayAverageChange": -1.3822203, "fiftyDayAverageChangePercent": -0.14652687, "twoHundredDayAverageChange": -1.5323257, "twoHundredDayAverageChangePercent": -0.15989499, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-05-16", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612967400000, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]